BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cai S, Yu T, Jiang Y, Zhang Y, Lv F, Peng J. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result. Clin Exp Med 2016;16:429-36. [PMID: 26164128 DOI: 10.1007/s10238-015-0373-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Chen P, Zheng C. Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B. Infect Drug Resist 2018;11:2179-85. [PMID: 30519055 DOI: 10.2147/IDR.S186719] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Zeng J, Cai S, Liu J, Xue X, Wu X, Zheng C. Dynamic Changes in Liver Stiffness Measured by Transient Elastography Predict Clinical Outcomes Among Patients With Chronic Hepatitis B. J Ultrasound Med 2017;36:261-8. [PMID: 27914175 DOI: 10.7863/ultra.15.12054] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
3 Wang X, Zhang W, Liu Y, Gong W, Sun P, Kong X, Yang M, Wang Z. Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma. Infect Agent Cancer. 2017;12:47. [PMID: 28852419 DOI: 10.1186/s13027-017-0153-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
4 Zhang W, Gong H, Su Z, Zhang X, Cao S. Risk factors associated with hepatic osteopathy in HBV related cirrhosis measured by liver stiffness: An Observational study. Medicine (Baltimore). 2019;98:e16628. [PMID: 31374030 DOI: 10.1097/md.0000000000016628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Liu H, Yang L. Dynamic change of depression and anxiety after chemotherapy among patients with ovarian cancer. Medicine (Baltimore) 2019;98:e16620. [PMID: 31374028 DOI: 10.1097/MD.0000000000016620] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
6 Ou H, Cai S, Liu Y, Xia M, Peng J. A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B. Therap Adv Gastroenterol 2017;10:207-17. [PMID: 28203279 DOI: 10.1177/1756283X16681707] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
7 Wu X, Zhou J, Xie W, Ding H, Ou X, Chen G, Ma A, Xu X, Ma H, Xu Y, Liu X, Meng T, Wang L, Sun Y, Wang B, Kong Y, Ma H, You H, Jia J. Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study. Infect Drug Resist 2019;12:745-57. [PMID: 31015765 DOI: 10.2147/IDR.S185120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
8 Zhang Y, Chen SW, Liu LL, Yang X, Cai SH, Yun JP. A model combining TNM stage and tumor size shows utility in predicting recurrence among patients with hepatocellular carcinoma after resection. Cancer Manag Res 2018;10:3707-15. [PMID: 30288102 DOI: 10.2147/CMAR.S175303] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
9 Guo R, Xie Y, Yang J, Lu H, Ye P, Jin L, Lin W. Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment. Sci Rep 2019;9:5916. [PMID: 30976044 DOI: 10.1038/s41598-019-42421-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Li Y, Zhang HX, Luo WD, Lam CWK, Wang CY, Bai LP, Wong VKW, Zhang W, Jiang ZH. Profiling Ribonucleotide and Deoxyribonucleotide Pools Perturbed by Remdesivir in Human Bronchial Epithelial Cells. Front Pharmacol 2021;12:647280. [PMID: 33995062 DOI: 10.3389/fphar.2021.647280] [Reference Citation Analysis]
11 Zhong C, Yin J, Zheng Z, Cai S, Gao Y. Risk factors associated with fatigue in chronic hepatitis B patients. Patient Prefer Adherence 2019;13:1065-72. [PMID: 31456634 DOI: 10.2147/PPA.S206953] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Cai S, Ou Z, Liu D, Liu L, Liu Y, Wu X, Yu T, Peng J. Risk factors associated with liver steatosis and fibrosis in chronic hepatitis B patient with component of metabolic syndrome. United European Gastroenterol J. 2018;6:558-566. [PMID: 29881611 DOI: 10.1177/2050640617751252] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 6.5] [Reference Citation Analysis]
13 Ge Z, Ma J, Qiao B, Wang Y, Zhang H, Gou W. Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality. Medicine (Baltimore) 2020;99:e21454. [PMID: 32769872 DOI: 10.1097/MD.0000000000021454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Xue X, Cai S, Ou H, Zheng C, Wu X. Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment. Patient Prefer Adherence 2017;11:85-93. [PMID: 28138226 DOI: 10.2147/PPA.S127139] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
15 He YJ, Xu H, Fu YJ, Lin JY, Zhang MW. Intraperitoneal hypertension, a novel risk factor for sepsis-associated encephalopathy in sepsis mice. Sci Rep 2018;8:8173. [PMID: 29802336 DOI: 10.1038/s41598-018-26500-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
16 Li H, Wang X, Tang J, Zhao H, Duan M. Decreased expression levels of ELOVL6 indicate poor prognosis in hepatocellular carcinoma. Oncol Lett 2019;18:6214-20. [PMID: 31788097 DOI: 10.3892/ol.2019.10974] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zhang E, Kosinska A, Lu M, Yan H, Roggendorf M. Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the "magic bullet" to kill cccDNA. Antiviral Res. 2015;123:193-203. [PMID: 26476376 DOI: 10.1016/j.antiviral.2015.10.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
18 Lu JB, Cai SH, Pan YH, Yun JP. Altered epidermal fatty acid-binding protein expression in hepatocellular carcinoma predicts unfavorable outcomes. Cancer Manag Res 2018;10:6275-84. [PMID: 30538573 DOI: 10.2147/CMAR.S181555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
19 Wang X, Liu Y, Sun J, Gong W, Sun P, Kong X, Yang M, Zhang W. Mitofusin-2 acts as biomarker for predicting poor prognosis in hepatitis B virus related hepatocellular carcinoma. Infect Agent Cancer 2018;13:36. [PMID: 30498519 DOI: 10.1186/s13027-018-0212-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
20 Chen P, Yang N, Xu L, Zhao F, Zhang M. Increased expression of protease-activated receptors 2 indicates poor prognosis in HBV related hepatocellular carcinoma. Infect Agent Cancer 2019;14:39. [PMID: 31768188 DOI: 10.1186/s13027-019-0256-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Chen Q, Cao C, Gong L, Zhang Y. Health related quality of life in stroke patients and risk factors associated with patients for return to work. Medicine (Baltimore) 2019;98:e15130. [PMID: 31008934 DOI: 10.1097/MD.0000000000015130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
22 Hu K, Li NF, Li JR, Chen ZG, Wang JH, Sheng LQ. Exosome circCMTM3 promotes angiogenesis and tumorigenesis of hepatocellular carcinoma through miR-3619-5p/SOX9. Hepatol Res 2021. [PMID: 34233088 DOI: 10.1111/hepr.13692] [Reference Citation Analysis]
23 Xie YD, Ma H, Feng B, Wei L. Efficacy of Real-world Entecavir Therapy in Treatment-naïve Chronic Hepatitis B Patients. Chin Med J (Engl) 2017;130:2190-7. [PMID: 28875955 DOI: 10.4103/0366-6999.213969] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
24 Sun W, Zhao S, Ma L, Hao A, Zhao B, Zhou L, Li F, Song M. Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission. BMC Gastroenterol 2017;17:51. [PMID: 28407735 DOI: 10.1186/s12876-017-0608-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
25 Yan Z, Qiao B, Zhang H, Wang Y, Gou W. Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study. Medicine (Baltimore) 2018;97:e11716. [PMID: 30075577 DOI: 10.1097/MD.0000000000011716] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
26 Sun J, Li Y, Sun X, Yu H, Liu Y. Dynamic Changes of the Aspartate Aminotransferase-to-Platelet Ratio and Transient Elastography in Predicting a Histologic Response in Patients With Chronic Hepatitis B After Entecavir Treatment. J Ultrasound Med 2019;38:1441-8. [PMID: 30244494 DOI: 10.1002/jum.14822] [Reference Citation Analysis]
27 Zheng JP, Miao HX, Zheng SW, Liu WL, Chen CQ, Zhong HB, Li SF, Fang YP, Sun CH. Risk factors for osteoporosis in liver cirrhosis patients measured by transient elastography. Medicine (Baltimore) 2018;97:e10645. [PMID: 29768330 DOI: 10.1097/MD.0000000000010645] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
28 Cai S, Li Z, Yu T, Xia M, Peng J. Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs. Infect Drug Resist 2018;11:469-77. [PMID: 29662321 DOI: 10.2147/IDR.S163038] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
29 Wang D, Yan X, Zhang M, Ren C, Wang L, Ma J, Guo L. Association between liver cirrhosis and estimated glomerular filtration rates in patients with chronic HBV infection. Medicine (Baltimore) 2020;99:e21387. [PMID: 32871988 DOI: 10.1097/MD.0000000000021387] [Reference Citation Analysis]
30 Cai S, Cao J, Yu T, Xia M, Peng J. Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine. Medicine (Baltimore) 2017;96:e7021. [PMID: 28562554 DOI: 10.1097/MD.0000000000007021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
31 Zeng J, Zheng C, Li H. Effectiveness of tenofovir or telbivudine in preventing HBV vertical transmission for pregnancy. Medicine (Baltimore) 2019;98:e15092. [PMID: 30946367 DOI: 10.1097/MD.0000000000015092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
32 Wu Y, Gao C, Cai S, Xia M, Liao G, Zhang X, Peng J. Circulating miR-122 Is a Predictor for Virological Response in CHB Patients With High Viral Load Treated With Nucleos(t)ide Analogs. Front Genet 2019;10:243. [PMID: 30967899 DOI: 10.3389/fgene.2019.00243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
33 Wang D, Zhang P, Zhang M. Predictors for advanced liver fibrosis in chronic hepatitis B virus infection with persistently normal or mildly elevated alanine aminotransferase. Exp Ther Med 2017;14:5363-70. [PMID: 29285064 DOI: 10.3892/etm.2017.5219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
34 Gao G, Sun B, Wang X, Wang S. Neutrophil to Lymphocyte Ratio as Prognostic Indicator for Patients with Esophageal Squamous Cell Cancer. Int J Biol Markers 2017;32:409-14. [DOI: 10.5301/ijbm.5000294] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
35 Xue X, Liao W, Xing Y. Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma. Infect Agent Cancer 2020;15:11. [PMID: 32082414 DOI: 10.1186/s13027-020-0273-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
36 Sun J, Li Y, Sun X, Liu Y, Zheng D, Fan L. Association between abdominal obesity and liver steatosis and fibrosis among patients with chronic hepatitis B measured by Fibroscan. Exp Ther Med 2019;18:1891-8. [PMID: 31410151 DOI: 10.3892/etm.2019.7727] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Huang M, Zhong J, Lu C, Deng F, Li L, Nong Y, Liang L, Qin H, Deng Y. Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy. Pharmgenomics Pers Med 2019;12:297-303. [PMID: 31695474 DOI: 10.2147/PGPM.S224256] [Reference Citation Analysis]
38 Zheng C, Yan H, Zeng J, Cai S, Wu X. Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B. Infect Drug Resist. 2019;12:845-854. [PMID: 31114265 DOI: 10.2147/idr.s195144] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
39 Zhao H, Song X, Li Z, Wang X. Risk factors associated with nonalcohol fatty liver disease and fibrosis among patients with type 2 diabetes mellitus. Medicine (Baltimore) 2018;97:e12356. [PMID: 30212992 DOI: 10.1097/MD.0000000000012356] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
40 Li Q, Chen L, Zhou Y. Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy. Clin Exp Med 2018;18:273-82. [PMID: 29350286 DOI: 10.1007/s10238-018-0486-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
41 Xiao YB, Cai SH, Liu LL, Yang X, Yun JP. Decreased expression of peroxisome proliferator-activated receptor alpha indicates unfavorable outcomes in hepatocellular carcinoma. Cancer Manag Res 2018;10:1781-9. [PMID: 29983595 DOI: 10.2147/CMAR.S166971] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
42 Guo YF, Pan JX, Zhuang WH. Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome. Infect Agent Cancer 2018;13:40. [PMID: 30559832 DOI: 10.1186/s13027-018-0215-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
43 Zheng Z, Liao W, Liu L, Cai S, Zhu H, Yin S. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study. Biomed Pharmacother 2020;122:109698. [PMID: 31918272 DOI: 10.1016/j.biopha.2019.109698] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
44 Liu Y, Wang X, Xiao J, Sun J, Zhang Y. Prognostic value of postoperative change in liver stiffness in patients with HBV-related hepatocellular carcinoma. J Int Med Res 2020;48:300060520908763. [PMID: 32290747 DOI: 10.1177/0300060520908763] [Reference Citation Analysis]